The clinical picture of moderate-to-severe thrombocytopenia and thrombotic complications at unusual sites occurring within 4 to 28 days of vaccination with the SARS-CoV-2 vaccines ChAdOx1 nCov-19 (Oxford-AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson) has been named vaccine-induced immune thrombotic thrombocytopenia (VITT) and several publications have followed the first case reports on March 28th , 2021 (1-5). The pathophysiology of VITT is not yet clearly understood.
Cerebral venous sinus thrombosis associated with COVID‐19 vaccine‐induced thrombocytopenia: Improvement in mortality rate over time